Laboratorios Farmaceuticos ROVI SA
OTC:LABFF

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Watchlist
Price: 90.61 USD Market Closed
Market Cap: 4.6B USD

Net Margin

16.7%
Current
Declining
by 3.8%
vs 3-y average of 20.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.7%
=
Net Income
€121.2m
/
Revenue
€724.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.7%
=
Net Income
$121.2m
/
Revenue
€724.2m

Peer Comparison

Country Company Market Cap Net
Margin
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
3.8B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.6B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.4B USD
Loading...

Market Distribution

In line with most companies in Spain
Percentile
67th
Based on 821 companies
67th percentile
16.7%
Low
-9 204.1% — 1.8%
Typical Range
1.8% — 19%
High
19% — 603.4%
Distribution Statistics
Spain
Min -9 204.1%
30th Percentile 1.8%
Median 7.6%
70th Percentile 19%
Max 603.4%

Laboratorios Farmaceuticos ROVI SA
Glance View

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

LABFF Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
16.7%
=
Net Income
€121.2m
/
Revenue
€724.2m
What is Laboratorios Farmaceuticos ROVI SA's current Net Margin?

The current Net Margin for Laboratorios Farmaceuticos ROVI SA is 16.7%, which is below its 3-year median of 20.5%.

How has Net Margin changed over time?

Over the last 3 years, Laboratorios Farmaceuticos ROVI SA’s Net Margin has decreased from 24.3% to 16.7%. During this period, it reached a low of 16.7% on Sep 30, 2025 and a high of 24.4% on Dec 31, 2022.

Back to Top